Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking

  • Kate Sheridan

By Kate Sheridan Aug. 23, 2022

Reprints
Adobe

Noted biotech investment firm OrbiMed slid from first place to 14th in STAT’s latest annual ranking of venture capital firm performance.

OrbiMed, which is based in New York City, is one of the most prominent players in the health care investing world. It manages $18 billion in assets, some of which the firm has invested in startups like Acceleron Pharma, which was acquired by Merck last year for $11.5 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

Create a display name to comment

This name will appear with your comment

A bionic pancreas aims to take the math out…
A bionic pancreas aims to take the math out of managing type 1 diabetes
New study sees possible link between aluminum in childhood…
New study sees possible link between aluminum in childhood vaccines and risk of asthma, but caveats…
Surgeons often take a fifth of the lungs to…
Surgeons often take a fifth of the lungs to remove a small tumor. There may be…
Medicare lays out the bureaucracy it will need to…
Medicare lays out the bureaucracy it will need to negotiate drug prices
Burning questions left unanswered about the latest Alzheimer’s therapy
Burning questions left unanswered about the latest Alzheimer’s therapy
An Alzheimer’s therapy scores winning results, but what could…
An Alzheimer’s therapy scores winning results, but what could it mean for patients?

Recommended Stories